Summary

There is no evidence of cardiovascular benefit that is associated with long-term treatment with nateglinide and valsartan in patients with impaired glucose tolerance and cardiovascular disease (CVD) or CV risk factors. However, valsartan therapy is associated with a reduction in the incidence of diabetes. This article discusses results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research [NAVIGATOR; NCT00097786] Trial.